Trial Profile
NCI-COG Pediatric MATCH (Molecular Analysis for Therapy Choice) - Phase 2 Subprotocol of BVD-523FB (Ulixertinib) in Patients With Tumors Harboring Activating MAPK Pathway Mutations
Status:
Active, no longer recruiting
Phase of Trial:
Phase II
Latest Information Update: 09 Nov 2023
Price :
$35
*
At a glance
- Drugs Ulixertinib (Primary)
- Indications CNS cancer; Glioma; Neuroblastoma; Non-Hodgkin's lymphoma; Rhabdomyosarcoma; Solid tumours
- Focus Therapeutic Use
- Acronyms A Pediatric MATCH Treatment Trial; NCI-COG Pediatric MATCH
- 13 Oct 2023 Planned End Date changed from 7 Apr 2024 to 30 Mar 2026.
- 20 Apr 2023 Planned End Date changed from 7 Apr 2023 to 7 Apr 2024.
- 07 Jun 2022 Results assessing efficacy in patients whose tumors harbored activating alterations in MAPK pathway from Arm J of this trial presented at the 58th Annual Meeting of the American Society of Clinical Oncology